Chongqing Zhifei Biological Products Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Rensheng Jiang

Chief Executive Officer (CEO)

CN¥900.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	14.8yrs
Participación del CEO	48.4%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

Recent updates

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Apr 26

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Mar 26

CEO

Rensheng Jiang (70 yo)

14.8yrs

Permanencia

CN¥900,000

Compensación

Mr. Rensheng Jiang is Chairman of the Board & CEO of Chongqing Zhifei Biological Products Co., Ltd. from June 2002. He joined the Chongqing Zhifei Biological Products Co., Ltd.in August 2009. He is Direct...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rensheng Jiang	Chairman of the Board & CEO	14.8yrs	CN¥900.00k	48.44% CN¥ 41.6b
Zhen Jing Li	VP, CFO & Director	6.1yrs	CN¥1.16m	sin datos
Fei Qin	VP, Secretary of Board & Director	6.1yrs	CN¥1.10m	sin datos
Lingfeng Jiang	Vice Chairman & VP	14.8yrs	CN¥1.10m	5.41% CN¥ 4.7b
Lin Yuan	Independent Director	no data	CN¥150.00k	sin datos
Xujiang Chen	Independent Director	2.9yrs	CN¥150.00k	sin datos
Lin Du	Non-Independent Director	7.1yrs	CN¥1.20m	sin datos
Shilong Yang	Non-Independent Director	5.8yrs	CN¥1.20m	sin datos
Yu Zhang	Employee Representative Supervisor	no data	sin datos	0.000080% CN¥ 68.7k
Tao Gong	Independent Director	2.7yrs	CN¥150.00k	sin datos

6.1yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de 300122 se considera experimentada (6 años de antigüedad promedio).

Chongqing Zhifei Biological Products Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chongqing Zhifei Biological Products Co., Ltd., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Consensus EPS estimates fall by 20%

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Price target decreased by 7.4% to CN¥65.91

Chongqing Zhifei Biological Products Co., Ltd., Annual General Meeting, Jun 18, 2024

Investor sentiment deteriorates as stock falls 15%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) announces an Equity Buyback for CNY 500 million worth of its shares.

Investor sentiment improves as stock rises 16%

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Price target decreased by 8.2% to CN¥67.08

Price target decreased by 7.7% to CN¥72.05

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 32%

EVE Energy Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 June 2023

Consensus revenue estimates increase by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Price target decreased to CN¥121

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on July 15, 2022

Investor sentiment improved over the past week

Chongqing Zhifei Biological Products Co., Ltd. Approves Cash Dividend for the Year 2021

Consensus forecasts updated

Price target decreased to CN¥148

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥193

Consensus EPS estimates increase by 10%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: EPS CN¥1.82 (vs CN¥0.61 in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥2.85 (vs CN¥0.62 in 2Q 2020)

Investor sentiment deteriorated over the past week

Price target increased to CN¥219

Consensus revenue estimates increase to CN¥26.1b

First quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 1Q 2020)

Investor sentiment deteriorated over the past week

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day high: CN¥167

Market bids up stock over the past week

Price target lowered to CN¥201

Market pulls back on stock over the past week

Market pulls back on stock over the past week

New 90-day high: CN¥166

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Chongqing Zhifei Biological Products Co.,Ltd. to Report Q3, 2020 Results on Oct 16, 2020

First half earnings released

New 90-day high - CN¥177

Chongqing Zhifei Biological Products Co.,Ltd. to Report First Half, 2020 Results on Aug 04, 2020

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad